In ALDHbr multiple myeloma cells, ALDH1A1 activates RXRα, which upregulates NIMA-related kinase 2 (NEK2), thereby activating the drug efflux pump and inducing resistance against bortezomib and doxorubicin [131]. Here, NEK2 is linked to plasma cell myeloma.